Navigation Links
GeneNews Announces First Quarter Results
Date:5/2/2008

ties (112,150) (11,684)

-------------------------------------------------------------------------

INVESTING ACTIVITIES

Additions to property, plant and equipment (213,104) (108,401)

-------------------------------------------------------------------------

Cash used in investing activities (213,104) (108,401)

-------------------------------------------------------------------------

Net increase (decrease) in cash and cash

equivalents during the period (2,162,624) (1,442,556)

Cash and cash equivalents, beginning of period 11,279,030 20,593,568

-------------------------------------------------------------------------

Cash and cash equivalents, end of period 9,116,406 19,151,012

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Supplemental cash flow information:

Interest received 95,958 163,353

Interest paid 30,528 35,490

-------------------------------------------------------------------------

-------------------------------------------------------------------------


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. GeneNews announces 2007 year end results
7. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6